The Democratic Republic of Congo (DRC) and neighboring Uganda are currently grappling with an active outbreak of Bundibugyo virus disease (BVD), a form of Ebola. Recent reports highlight a concerning acceleration in case numbers and a wider geographical spread within the DRC, prompting intensified public health measures. While Uganda has also recorded cases, primarily linked to the DRC, its immediate situation appears more stable, with no new cases reported for several days. ### Understanding Bundibugyo Virus Disease Bundibugyo virus disease is a severe and often deadly illness caused by the Bundibugyo virus, which belongs to the same family as other Ebola viruses. It is considered a zoonotic disease, meaning it originates in animals and can then spread to humans. Scientists suspect fruit bats are the natural carriers of the virus. Human infection typically occurs when people come into close contact with the blood or other bodily fluids of infected wild animals, such as bats or non-human primates. Once a person is infected, the virus can spread very quickly from one individual to another through direct contact with blood, secretions, organs, or other bodily fluids of someone who is sick, or from contaminated surfaces and objects. A major concern for spread is in healthcare settings, especially if proper infection prevention and control (IPC) measures are not strictly followed. Unsafe burial practices, which often involve direct contact with the deceased, also significantly increase the risk of transmission. The incubation period for BVD, the time from infection to symptom onset, can range from two to 21 days. Crucially, individuals are not contagious until they begin to show symptoms, which include an initial phase of fever, extreme tiredness, muscle aches, headaches, and a sore throat. These early signs are quite common and can be mistaken for other illnesses like malaria, making early diagnosis challenging. As the disease progresses, patients may experience severe gastrointestinal symptoms, organ failure, and in some cases, internal and external bleeding. ### The Outbreak's Grip on the Democratic Republic of Congo The Democratic Republic of Congo faces the most significant burden of this BVD outbreak. As of early June, the country had reported a cumulative total of 676 confirmed cases, tragically including 136 deaths. This translates to a case fatality rate of over 20%, though experts believe the actual number of deaths may be higher as some prior fatalities before the outbreak was officially declared are still under investigation. The outbreak's epicenter remains in Ituri Province, which accounts for a substantial 93% of all confirmed cases. However, the virus has shown worrying signs of spreading, with cases now confirmed across 29 health zones in Ituri, North Kivu, and South Kivu provinces. Response teams are working tirelessly to trace contacts, with thousands identified and under active monitoring across these affected regions. A significant challenge in the DRC is the complex humanitarian environment, marked by ongoing conflict and a highly mobile, often displaced population. These factors, combined with security incidents affecting health facilities, create immense operational hurdles for health workers. Access to certain areas is constrained, surveillance activities can be disrupted, and there's a heightened risk of undetected virus transmission. This underscores the critical need for local leadership and strong community involvement to effectively manage the crisis. ### Uganda's Vigilance Against Cross-Border Transmission Uganda has also registered cases of Bundibugyo virus disease, with 19 confirmed infections and two deaths attributed to imported cases, along with one probable death. Notably, Uganda has not reported any new confirmed cases in the past six days, indicating that initial containment efforts may be proving effective. All confirmed cases in Uganda are epidemiologically linked to transmission originating in the Democratic Republic of Congo. Most are imported cases, with a smaller number representing secondary transmission among contacts and healthcare workers who cared for these imported patients. The cases have been identified in the Kampala Metropolitan Area, specifically in Kampala and Wakiso districts. Crucially, there has been no documented evidence of widespread community transmission within Uganda. The primary exposure risks identified include healthcare settings and cross-border movements between the two nations. Ugandan health authorities are diligently tracing contacts; of the over 800 identified, many have either completed their 21-day follow-up period or are under active monitoring. ### Comprehensive Public Health Response In both the Democratic Republic of Congo and Uganda, national health authorities are working hand-in-hand with the World Health Organization (WHO) and other international partners to implement a robust and comprehensive public health response. This includes executing a continental response plan, actively engaging donors, and mobilizing essential resources to address funding gaps and sustain critical operations in affected and at-risk areas. Key strategies involve rapid case identification, immediately isolating infected individuals, and providing supportive care. Given that there are currently no approved vaccines or specific treatments for BVD, these measures, alongside meticulous contact tracing, ensuring safe burial practices, and fostering strong community engagement, are paramount to controlling the outbreak. In the DRC, detailed risk assessments are guiding operational priorities, identifying a large number of health zones as either affected or at risk, highlighting the immense scale of the required response. ### Advancing Towards Treatments: Clinical Trials Despite the absence of approved treatments, significant scientific efforts are underway. Following recommendations from WHO advisory groups, both countries are supporting a clinical trial to evaluate potential therapeutics. This includes testing investigational treatments like MBP134 and REGN3479 for infected patients, and considering obeldesivir for post-exposure prophylaxis – a preventative measure for individuals who may have been exposed to the virus. These trials are being conducted under the highest ethical standards, with national health authorities leading the process in close consultation with affected communities. The protocol for the trial is currently undergoing review by ethics committees and regulatory bodies in both nations, underscoring the collaborative push for new medical interventions. ### Assessing and Mitigating Risks The WHO has recently updated its risk assessment for the Bundibugyo virus outbreak. The risk level in the Democratic Republic of Congo remains categorized as very high due to the persistent transmission and the continued spread into new health zones, which heightens the potential for further national and regional dissemination. For Uganda, the risk is assessed as high, owing to the confirmed cross-border spread and the historical epidemiological connections along the eastern DRC–western Uganda corridor, a region that has faced Ebola outbreaks in the past. Countries sharing land borders with the DRC and Uganda are also considered to be at high risk. This is primarily due to substantial population movement linked to cross-border trade and mining activities, coupled with varying levels of preparedness and experience in responding to BVD among these nations. For the broader African region and at a global scale, the risk is currently assessed as low. The WHO has advised against imposing any restrictions on travel or trade with the Democratic Republic of Congo or Uganda, based on the current available information, emphasizing that such restrictions can hinder response efforts and negatively impact affected populations. ### Protecting Communities: Essential WHO Advice To effectively contain and manage the BVD outbreak, the WHO provides several critical recommendations. These include strengthening coordinated outbreak control measures, enhancing cross-border collaboration between neighboring countries, and maintaining robust surveillance and preparedness activities. The goal is to prevent further regional spread and ensure a highly effective public health response. Key to this is the consistent application of infection prevention and control practices in all settings, particularly in healthcare facilities and during burial rites. Community engagement and education are vital to ensure public understanding, cooperation, and adherence to public health guidance. Continuous monitoring, prompt laboratory testing, and isolation of suspected cases are foundational pillars of the response. The global health community, through WHO expert groups, continues to evaluate candidate vaccines and therapeutics for BVD, indicating ongoing research and development efforts to arm the world with better tools against this formidable virus. Regular information products and situation reports are being issued to keep the public and health professionals informed on the evolving situation, reinforcing transparency and coordinated action.